Our Science and Pipeline

Indication: Targeted Moderate-to-Severe Dermatological Conditions

Current Stage: IND-Enabling / CMC Phase

DB01 is our lead systemic asset designed to target the underlying biological pathways of chronic skin disorders from within. Dermalbright Pharma has successfully concluded its FDA Pre-IND meeting, aligning our clinical development plan with federal regulatory frameworks.

The program is currently progressing through the advanced CMC (Chemistry, Manufacturing, and Controls) Phase, ensuring robust, scalable, and ultra-pure manufacturing protocols. With the therapeutic formulation now optimized and finalized, the team is actively compiling the final data packages to submit the Investigational New Drug (IND) application.

Indication: Companion Therapy & Remission Maintenance

Current Stage: Formulation & Pre-Clinical Design

DB02 represents our front-line, external defense system. Formulation has officially commenced on this advanced OTC topical cream, engineered to seamlessly integrate into a multi-tiered clinical protocol.

Rather than acting as a standalone product, DB02 is strategically designed as a synergistic companion therapy to assist and amplify the efficacy of oral DB01 during the acute treatment phase. Following successful clearance, DB02 acts as a long-term maintenance system, providing continuous epidermal defense to lock in treatment outcomes and prevent condition relapse.